Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133213 | 0.97 | ADORA2A (0.64) | ADORA2AHSD11B1SLC6A9SLC6A5 | |
| SCHEMBL1355638 | 0.79 | ADORA2A (0.73) | ADORA2AHSD11B1 | |
| SCHEMBL1353175 | 0.79 | ADORA2A (0.64) | ADORA2A | |
| SCHEMBL1355537 | 0.78 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL1355331 | 0.78 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL1355307 | 0.78 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL1354665 | 0.78 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL1355414 | 0.78 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL1353258 | 0.78 | ADORA2A (0.66) | ADORA2A | |
| SCHEMBL1353250 | 0.77 | ADORA2A (0.64) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | claimed |
| US-9029393-B2 | Adenosine receptor ligands and uses thereof | KALDI PHARMA, SAS (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2391625-B1 | New adenosine receptor ligands and uses thereof | DOMAIN THERAPEUTICS (FR) | 2013-05-01 | — | — | EP | disclosed |
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | DOMAIN THERAPEUTICS (FR) | 2011-11-24 | — | — | US | disclosed |
| EP-2210891-A1 | New adenosine receptor ligands and uses thereof | Domain Therapeutics (FR) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288074-A1 | NEW ADENOSINE RECEPTOR LIGANDS AND USES THEREOF | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885HSD11B1 2224/4885SLC6A9 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.